S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians

Pharmacogenetics

Volumn 6, Issue 6, 1996, Pages 521-526

  Persson, Irene ^b   Aklillu, Eleni ^a   Rodrigues, Fredrick ^a   Bertilsson, Leif ^c   Ingelman Sundberg, Magnus ^b  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cytochrome P450; genetic polymorphism; genotype; mephenytoin; omeprazole; proguanil

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DNA; MEPHENYTOIN;

ALLELE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; DRUG METABOLISM; DRUG URINE LEVEL; ENANTIOMER; ETHIOPIA; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RACE;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ETHIOPIA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0030462277     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199612000-00005     Document Type: Article

References (38)

1. Adedoyin A, Prakash C, O'Shea D, Blair IA, Wilkinson GR. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 1994: 4, 27-38.
2. Aklillu E, Persson I, Bertilsson L, Johansson, I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996: in press.
3. Alvàn G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of deberisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990: 39, 533-537.
4. Andersson T, Regårdh CG, Daal-Pustinene ML, Bertilsson L. Slow omeprazol metabolisers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990: 12, 415-416.
5. Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 1994: 4, 73-81.
6. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in regulation of diazepam metabolism: relation to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1989: 45, 348-355.
7. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994: 37, 413-420.
8. Brøsen K, Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993: 36, 105-108.
9. Brøsen K, de Morals SM, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995: 5, 312-317.
10. Cavalli-Sforza LL, Piazza A, Menozzi P, Mountain J. Reconstruction of human evolution: Bringing together genetic, archaeological, and linguistic data. Proc Natl Acad Sci USA 1988: 85, 6002-6006.
11. Chang M, Dahl M-L, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians; comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995: 5, 358-363.
12. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996: 6, 193-201.
13. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994: 4, 285-299.
14. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4-hydroxylase in humans. Biochemistry 1994: 33, 1743-1752.
15. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou H, Zhou B, Liao C, Zhang L. Metoprolol and mephenytoin oxidation polymorphisms in far eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989: 46, 198-207.
16. Johansson I, Oscarsson M, Yue Q-Y, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Molec Pharmacol 1994: 46, 452-459.
17. Kupfer A, Roberts K, Schenker S, Branch RA. Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther 1981:218, 193-199.
18. Kupfer A, Desmond PV, Schenker S, Branch RA. Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. J Pharmacol Exp Ther 1982: 221, 590-597.
19. Masimirembwa C, Bertilsson L, Johansson I, Hasler J, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995: 57, 656-661.
20. Mokhtar G. General history of Aftica: II Ancient civilizations of Africa. Abridged edition. Paris: UNESCO, 1990.
21. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mehenytoin metabolism in humans. J Biol Chem 1994a: 269, 15419-15422.
22. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology 1994b: 46, 594-598.
23. de Morais SMF, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995: 58: 404-411.
24. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985: 38, 402-408.
25. Pollock BG, Perel JM, Kirshnere M, Altier LP, Yeager AL, Reynolds CF. S-mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol 1991: 40, 609-611.
26. Price Evans DA, Krahn P, Narayanan N. The mephenytoin (cytochrome P450 2C19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmogenetics 1995: 5, 64-71.
27. Sanz EJ, Villèn T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. Clin Pharmacol Ther 1989: 45, 495-499.
28. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T. Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4′-hydroxylation recruited from an Indonesian population. Br J Clin Pharmacol 1995: 39, 297-303.
29. Skjelbo E, Brosen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partly responsible for the N-demetylation of imipramine. Clin Pharmacol Ther 1991: 49, 18-23.
30. Skjelbo E, Gram LF, Brosen K. The N-demetylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study. Br J Clin Pharmacol 1993: 35, 331-334.
31. Tybring G, Bertilsson L. A methodological investigation of the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 1992: 2, 241-243.
32. Ward SA, Walle T, Walle UK. Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. Clin Pharmacol Ther 1989: 45, 72-79.
33. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the oxidation of polymorphism - a panel study. Br J Clin Pharmacol 1991: 31, 689-692.
34. Wedlund PJ, Aslanian WS, Mcallister CB, Wilkinson GR, Branch A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984a: 36, 773-780.
35. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA, Wilkinson GR. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Cromatogr 1984b: 307, 121-127.
36. Wedlund PJ, Sweetman BJ, Wilkinson GR, Branch RA. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Disp 1987: 15, 277-279.
37. Wrighton SA, Stevens JC, Becker GW, Vanden Branden M. Isolation and characterization of human liver cytochrome P450 2C19. Correlation between 2C19 and S-mephnytoin 4-hydroxylation. Arch Biochem Biophy 1993: 306, 240-245.
38. Zhang Y, Biouhin RA, McNamara P, Steinmez J, Wedlund P. Limitation to the use of the urinary S/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991: 31, 350-352.